Impulse Control Disorder
10
5
5
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 29/100
10.0%
1 terminated out of 10 trials
66.7%
-19.9% vs benchmark
30%
3 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (10)
Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders
Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease
rTMS Over the Dorsolateral Prefrontal Cortex for the Treatment of Impulse Control Disorders in Parkinson's Disease
Feasibility of Accelerated, Personalized rTMS as an Adjuvant for Impulse Control Disorders: a Pilot Study
Neurostimulation Versus Therapy for Problems With Emotions
STIMPulseControl Ancillary Speech Study
Frontosubthalamic Networks in Parkinson's Disease.
Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa
Effects of Non-invasive Brain Stimulation in Impulse Control Disorders
Naltrexone for Impulse Control Disorders in Parkinson's Disease